论文部分内容阅读
[目的]探讨原发性胃弥漫大B细胞淋巴瘤(PG-DLBCL)的生存情况及预后影响因素.[方法]回顾分析41例PG-DLBCL患者的临床资料,应用Kaplan-Meier法进行生存分析及单因素分析.[结果]41例PG-DL-BCL患者1年、2年、3年总生存率分别为77.3％、62.8％、62.8％.单纯手术治疗预后不良;化疗6周期以上的PG-DLBCL患者,单纯化疗与手术联合化疗的生存率相比较差异无显著性(P＞0.05);化疗6周期以上者生存率明显高于化疗6周期以下者(P＜0.05);R-CHOP化疗方案预后优于CHOP方案.单因素分析显示B症状、Lu-gano分期的ⅡE～Ⅳ期、国际预后指数(IPI)评分3～5分、外周血中性粒细胞与淋巴细胞比值(NLR)≥3.5、CA125增高、乳酸脱氢酶(LDH)升高是PG-DLBCL患者预后不良的影响因素(P＜0.05).[结论]B症状、Luga-noⅡE～Ⅳ期、IPI3～5分、外周血NLR≥3.5、CA125增高、LDH水平升高是PG-DLBCL预后不良的影响因素.治疗上推荐以化疗为主的方案,化疗疗程在6周期以上及加用利妥昔单抗的化疗方案可改善患者预后.“,”[Objective]To analyze the clinical characteristics,survival and prognostic factors of primary gas-tric diffuse large B-cell lymphoma(PG-DLBCL).[Methods]The clinical data of 41 patients with PG-DLBCL were retrospectively analyzed.we applied Kaplan-Meier to estimate the survival time of all patients.[Results] Among the 41 patients,the OS(overall survival)rate at 1-,3-,and 5 years were 77.3％,62.8％,55.0％,respectively.Patients with surgery alone had very poor diagnosis.In PG-DLBCL patient with over 6 cycles of chemotherapy,there was no significant difference in the survival rate between chemotherapy alone and surgery combined chemo-therapy(P ＞0.05).Patients with more than 6 cycles of chemotherapy had a significantly higher survival rate than patients under chemotherapy for 6 cycles(P ＜0.05).The prognosis of R-CHOP chemotherapy was better than CHOP.Univariate analysis showed that B-symptoms,Lugano stage ⅡE～Ⅳ,IPI(International Prognosis Index)score of 3-5 points,peripheral blood NLR ≥ 3.5,high CA125,and LDH levels were predictors for poor progno-sis in patients with PG-DLBCL(P ＜0.05).[Conclusion]B symptoms,Lugano staging of ⅡE～Ⅳ,IPI score of 3～5 points,peripheral blood NLR≥3.5,increased CA125,and elevated LDH level were important influencing fac-tors for poor prognosis of PG-DLBCL(P ＜0.05).Chemotherapy-based treatment program is recommended.Chem-otherapy regimen of more than 6 cycles and chemotherapy with rituximab can improve the prognosis of patients.